Anergen, Inc.

Calyx Therapeutics, Inc.

Theracos, Inc.

Research Institute of Palo Alto Medical Foundation

Indian Institute of Technology Bombay

Palo Alto Medical Foundation

Amergen, Inc.

Natpro, Inc.

Somesh D Sharma

Bishwajit Nag

Brian R Clark

Subramaniam Sriram

L Bernard Lerch

Jack S Remington

Satyanarayana Medicherla

Jeffrey B Prince

Fausto G De Araujo

John Bright

Bernard L Lerch

Debendranath Dey

Partha Neogi

Harden M McConnell

Ananda Sen

Neelam Vishwanath Dwivedi

Prabha V Mukku

Teresa Kendrick

Jayesh Bellare

Arunagirinathan Manickam Adhimoolam

An orally administrable pharmaceutical preparation containing a protein. More particularly, an orally administrable pharmaceutical preparation including a protein loaded on metal oxide nanoparticles and an amino acid; wherein the amino acid forms an adduct with the protein loaded on metal oxide nanoparticles. An process for the production of the afore-mentioned orally administrable pharmaceutical preparation is also disclosed.

Orally administrable pharmaceutical preparation containing protein

A water soluble extract ofnamed MC6, methods for its preparation and methods for its use in the treatment of hyperglycemic disorders are provided. The active MC6 is characterized by moving as a single band on SDS-PAGE having a molecular weight of less than 10 kDal, and by comprising three peptides. Also provided is a peptide component of MC6 named MC6.1, as well as analogues and mimetics thereof. The active MC6, MC 6.1, MC6.2, and MC6.3 exhibit hypoglycemic activity, even following oral administration. Also provided are methods of using the active agents to treat hyperglycemic disorders, particularly diabetes, where the active agents are preferably orally administered.

Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes

Substituted isoquinolines, isochromanones and isothiochromanones that inhibit the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6) and/or the enzyme cyclooxygenase-2 (COX-2) and/or interleukin-10 (IL-10). Compositions containing such compounds and methods of using such compounds for treatment and/or prevention of inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by TNF-alpha, IL-6, COX-2 and/or IL-10 are also disclosed.

Tricyclic compounds and uses thereof

Protein kinase inhibitor

The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

MHC conjugates useful in ameliorating autoimmunity

A water soluble extract of named MC6, methods for its preparation and methods for its use in the treatment of hyperglycemic disorders are provided. The active MC6 is characterized by moving as a single band on SDS-PAGE having a molecular weight of less than 10 kDal, and by comprising tree peptides. Also provided is a peptide component of MC6 named MC6.1, as well as analogues and mimetics thereof. The active MC6, MC6.1, MC6.2, and MC6.3 exhibit hypoglycemic activity, even following oral administration. Also provided are methods of using the active agents to treat hyperglycemic disorders, particularly diabetes, where the active agents are preferably orally administered.

Disclosed herein are compounds of the formula I

A water soluble extract of M.charantia named MC6, methods for its preparation and methods for its use in the treatment of hyperglycemic disorders are provided. The active MC6 is characterized by moving as a single band on SDS-PAGE having a molecular weight of less than 10 kDal, and by comprising three peptides. Also provided is a peptide component of MC6 named MC6.1, as well as analogues and mimetics thereof. The active MC6, MC6.1, MC6.2, and MC6.3 exhibit hypoglycemic activity, even following oral administration. Also provided are methods of using the active agents to treat hyperglycemic disorders, particularly diabetes, where the active agents are preferably orally administered.

Orally active fraction of momordica charantia, active peptides thereof,

The present invention provides immunogenic oligopeptides derived from the Major Histocompatibility Complex (MHC) glycoprotein protein sequences for use in compositions and methods for the treatment, prevention and diagnosis of deleterious immune responses, such as autoimmunity and allergies. The peptides are capable of inducing an immune response against glycoproteins encoded MHC alleles associated with the target disease. In preferred embodiments the peptides of the invention are derived from hypervariable region of the .beta. chain of an MHC Class II molecule associated with the deleterious immune response.

Vaccination with peptide of MHC class II molecules for treatment of

A compound of the formula I ##STR1## wherein A and C are independently H, alkyl of 1-6 carbon atoms, hydroxy, or alkoxy of 1-6 carbon atoms;

The present invention is directed to complexes comprising an isolated MHC subunit component, an antigenic peptide and, in some cases, an effector component. The antigenic peptide is associated with the antigen binding site of the MHC subunit component. These complexes are useful in treating autoimmune disease.

MHC class II .beta. chain/peptide complexes useful in ameliorating

Genetic material encoding the P28 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.

Growing community of inventors

Los Altos, CA, United States of America

Somesh D Sharma